Browse OB/GYN Clinical Alert Articles by Topic

Is Routine Voiding Necessary Following Minimally Invasive Hysterectomy?

This unblinded, randomized clinical trial of patients undergoing minimally invasive benign nonurogynecologic hysterectomy with anticipated same-day discharge demonstrated that eliminating the requirement to void prior to discharge reduced time spent in the post-anesthesia care unit by 27.14 minutes (173.26 mins no void vs. 201.95 mins void; P = 0.002) without increasing the proportion of patients with postoperative urinary retention (3% void vs. 1% no void; P = 3.69).

A Closer Look at a New Low-Dose Copper IUD

This study reports on the three-year data from an ongoing Phase III study evaluating the efficacy, safety, and tolerability of a new low-dose copper intrauterine device (IUD), demonstrating low rates of expulsion and discontinuation and expanding the nonhormonal IUD options available in the United States.

Updates on Cervical Cancer Prevention: Summary and Projected Effect

HPV vaccination and updated screening strategies offer OB/GYN providers powerful tools to prevent cervical cancer. Recent advances, risk-based management, and enhanced follow-up can provide targeted care for high-risk patients to reduce the incidence of cervical cancer while avoiding unnecessary procedures.

Postoperative Antibiotics After Cesarean Delivery to Reduce SSI

This randomized, double-blind clinical trial including 321 women with a pre-pregnancy body mass index > 30 kg/m² demonstrated no difference in surgical site infection composite between participants receiving oral cephalexin and metronidazole for 48 hours after cesarean delivery compared to placebo (5.6% vs. 6.8%; odds ratio, 0.80; 95% confidence interval, 0.33-2.22; P = 0.64).

Adverse Outcomes in Women with a History of Recurrent Pregnancy Loss

Women with a history of recurrent pregnancy loss are at significantly increased risk of adverse outcomes, including preeclampsia, placental abruption, cesarean delivery, preterm birth, stillbirth, and perinatal mortality.

What Is the Genitourinary Syndrome of Lactation?

In this systematic review of 65 studies, the prevalence of vaginal atrophy among postpartum breastfeeding patients was 63.9% (95% confidence interval [CI], 55.3% to 71.6%) and vaginal dryness symptoms occurred in 53.6% (95% CI, 33.6% to 72.5%). Dyspareunia also was elevated, with a prevalence of 60.0% at three months, (95% CI, 45.1% to 73.3%), 39.7% at six months, (95% CI, 28.9% to 51.5%), and 28.5% at 12 months (95% CI, 26.3% to 30.9%).

Gepotidacin Tablets (Blujepa)

The U.S. Food and Drug Administration has approved gepotidacin, a first-in-class antibacterial medication for the treatment of uncomplicated urinary tract infections. It is the first new class of oral antibiotics approved in nearly 30 years.

Can Hyperemesis Gravidarum Be Prevented with Metformin?

Although differences were not statistically significant, women with pre-conceptional metformin exposure appeared to have lower rates of hyperemesis gravidarum and comparable nausea and vomiting symptom severity, suggesting a potential protective effect that warrants further investigation in larger, adequately powered studies.

What Are Period Pills?

In this national survey of almost 7,000 people aged 15 to 49 years who were assigned female sex at birth, conducted between December 2021 and January 2022, one-quarter of participants (24%; 95% confidence interval [CI], 22%, 25%) stated that they would personally use period pills and about half of the respondents (52%; 95% CI, 50%, 53%) were in favor of the availability of period pills.

Intrauterine Hemorrhage-Control Devices for Postpartum Hemorrhage

This multicenter, prospective, observational study comparing intrauterine balloon tamponade vs. vacuum-induced devices for postpartum hemorrhage demonstrated no difference in blood loss after device placement (median quantitative blood loss, 194 mL balloon vs. 240 mL vacuum; P = 0.40), need for blood transfusion (59.7% balloon vs. 50.0% vacuum; P = 0.08), need for more than three units of packed red blood cells (27.0% balloon vs. 24.9% vacuum; P = 0.53), or device failure (7.7% balloon vs. 8.5% vacuum; P = 0.70).